Bausch Health Companies Inc. (BHC) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong growth in Bausch + Lomb and international segments, and strategic initiatives like debt refinancing and acquisitions bolster long-term prospects. Despite some revenue declines and conservative guidance adjustments, positive Q&A insights on Xifaxan's growth and RED-C trials suggest optimism. Market reaction should be positive, with a projected 2-8% stock price increase, considering the company's market cap and strategic positioning.
Key Financial Performance
Revenue (Consolidated) $2.681 billion, up 7% on a reported basis and 5% on an organic basis year-over-year. Growth attributed to strong performance across segments.
Adjusted Gross Margin 72.7%, a decrease of 40 basis points year-over-year. No specific reason for the decrease mentioned.
Adjusted Operating Expenses $1.024 billion, an increase of $41 million year-over-year. No specific reason for the increase mentioned.
Adjusted EBITDA (Consolidated) $986 million, an increase of $77 million or 8% year-over-year. Growth attributed to operational performance.
Adjusted Operating Cash Flow (Consolidated) $508 million. No year-over-year change or reason mentioned.
Revenue (Bausch Health excluding Bausch + Lomb) $1.4 billion, up 7% on a reported basis and 5% on an organic basis year-over-year. Growth attributed to strong performance in Solta and Salix businesses.
Adjusted EBITDA (Bausch Health excluding Bausch + Lomb) $773 million, up 7% year-over-year, including an $81 million R&D charge. Excluding the charge, adjusted EBITDA grew 18% year-over-year.
Adjusted Operating Cash Flow (Bausch Health excluding Bausch + Lomb) $347 million, up 1% year-over-year. Limited growth due to timing in working capital.
Revenue (Salix) $716 million, up 12% on a reported basis and 11% on an organic basis year-over-year. Growth driven by Xifaxan volume growth and one-time net pricing favorability.
Revenue (International Segment) $286 million, down 2% on a reported basis and 4% on an organic basis year-over-year. Decline due to market softness in Mexico and nonrecurrence of Wellbutrin orders in Canada.
Revenue (Solta Medical) $140 million, up 25% on a reported basis and 24% on an organic basis year-over-year. Growth driven by strong performance in the Asia Pacific region, particularly South Korea.
Revenue (Diversified Segment) $258 million, down 4% on a reported basis and 6% on an organic basis year-over-year. Decline driven by nonrecurrence of prior year orders for Cardizem and challenges in neurology.
Revenue (Bausch + Lomb) $1.3 billion, up 7% on a reported basis and 6% on an organic basis year-over-year. Growth attributed to strong performance across the segment.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Cabtreo: Achieved triple-digit growth and became the #1 prescribed topical branded acne product in new brand patient starts. 105,000 new patients prescribed year-to-date, up 69% over the prior year.
Ryaltris: Achieved triple-digit growth.
Xifaxan: Delivered double-digit growth, with a 16% revenue increase in Q3. 71,000 new patients started in Q3, up 14% year-over-year.
Thermage: Received medical device licensing clearance in Canada and surpassed 1,000 unit installed base milestone in Korea.
Fraxel FTX: Launched in April 2025 in the U.S. with global expansion planned.
Solta Medical: Achieved 25% revenue growth, driven by strong performance in South Korea (96% growth) and double-digit growth in the U.S., EMEA, and Canada.
Salix: Achieved 12% revenue growth, driven by Xifaxan volume growth and favorable pricing.
Revenue Growth: Bausch Health (excluding Bausch + Lomb) achieved 7% revenue growth on a reported basis and 5% on an organic basis.
Debt Reduction: Reduced debt by $600 million using cash on hand.
Adjusted EBITDA: Grew 7% year-over-year, or 18% excluding a $81 million R&D charge.
DURECT Acquisition: Acquired DURECT Corporation, adding larsucosterol to the R&D pipeline for treating alcohol-associated hepatitis (AH). Phase III study planned for early 2026.
RED-C Development: Continued progress on two global Phase III studies for RED-C, targeting overt hepatic encephalopathy, with data expected by early 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macroeconomic Environment: Uncertainty in the macroeconomic environment, particularly in China, has led to cautious consumer behavior in the aesthetics market, potentially impacting revenue growth.
Geographic Performance Variability: Mixed performance in international markets, with declines in Canada and Latin America due to factors like market softness in Mexico and reduced orders for certain products.
Payer Coverage Challenges: Relistor continues to face a challenging payer coverage environment, which could hinder its growth potential.
Revenue Dependence on Key Markets: Solta's revenue is heavily dependent on the Asia Pacific region, particularly South Korea, which could pose risks if demand in this region declines.
Regulatory and R&D Risks: The development of new treatments like larsucosterol and RED-C involves significant R&D investment and regulatory hurdles, with no guarantee of successful commercialization.
Debt and Capital Structure: Despite reducing debt by $600 million, the company still faces challenges in optimizing its capital structure and managing long-term financial obligations.
Product-Specific Risks: The dermatology segment's growth is partly driven by new products like Cabtreo, which may face competitive pressures or market adoption challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has raised its full-year revenue guidance to be between $5 billion and $5.1 billion, reflecting a midpoint increase of $25 million and a 4% year-over-year growth.
Adjusted EBITDA Guidance: The adjusted EBITDA outlook has been increased to a range of $2.7 billion to $2.75 billion, excluding the impact of core IP R&D, representing a 7% increase compared to 2024.
Adjusted Operating Cash Flow Guidance: The adjusted operating cash flow is now expected to be between $975 million and $1.025 billion, with the midpoint raised by $150 million.
Xifaxan Growth: Xifaxan's growth is expected to continue, driven by both volume and price increases across all indications, supported by enhanced marketing and AI-driven customer insights.
Solta Medical Segment: The Solta Medical segment is anticipated to maintain its growth trajectory, with significant contributions from the Asia Pacific region and expansion in the U.S. and European markets. New product launches, such as Fraxel FTX, are expected to drive future growth.
DURECT Acquisition and Pipeline: The acquisition of DURECT Corporation adds larsucosterol to the R&D pipeline, with a Phase III study for alcohol-associated hepatitis planned to begin by early 2026. This is expected to enhance the company's hepatology portfolio.
RED-C Development: The company is on track with two global Phase III studies for RED-C, a potential next-generation treatment for overt hepatic encephalopathy, with initial data readouts expected by early 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why is the revenue growth for Xifaxan outpacing script growth?
A:The revenue growth for Xifaxan is outpacing script growth due to a one-time benefit associated with the gross-to-net accrual, influenced by the exit of 340B and Medicaid. Typically, year-over-year pricing for Xifaxan is in the mid-single digits. Volume growth is balanced across all channels, with strong new patient starts and benefits from an AI-driven engine optimizing call points.
Q:Which channel is mostly driving the overall script growth for Xifaxan, and how durable is this growth profile?
A:The total TRx growth for Xifaxan was 9% in the quarter, with non-retail extended units at 20% and total extended units at 11%. New-to-brand growth was 14%, driven by investments in direct-to-consumer initiatives and an AI engine. The growth profile is supported by these investments and strategies.
Q:What is the impact of CMS price negotiations on Xifaxan and Medicare Part D?
A:Negotiations with CMS have concluded, and the agreed pricing will be published on November 30, 2025. 30% of Xifaxan's volume goes through Medicare Part D. The company has implemented mitigation strategies to reduce financial impact, and the average EBITDA for 2026-2027 is expected to be similar to 2025.
Q:Are there any plans for manufacturing in the U.S. regarding MFN?
A:Currently, there are no plans for manufacturing in the U.S. Xifaxan is produced in Canada, and its active ingredient originates from Italy. There are no material tariffs imposed on the flow of products at this time.
Q:Why was the guidance for the top line only slightly increased despite strong performance in multiple pharma sets?
A:The guidance was only slightly increased due to one-time benefits in Q3, such as adjustments to gross-to-net rebates. The fourth quarter is expected to align with prior expectations, and the increase in guidance reflects positive trends and improved free cash flow conversion.
Q:Why was SG&A spend unusually low in Q3, and what should be the expected run rate?
A:SG&A spend in Q3 was unusually low due to nonrecurring changes to accruals. The run rate for SG&A should be based on the first two quarters of the year.
Q:What is the status of the Phase III results for RED-C, and what are the expectations for the trial?
A:The two global Phase III studies for RED-C are fully enrolled, and the readout for both trials will occur in early 2026. The primary and secondary endpoints are important, and the program targets a large patient population with cirrhosis. The company will provide data in totality once available.
Q:What is the expected erosion curve for Xifaxan generics post-2028?
A:The erosion curve for Xifaxan generics post-2028 is expected to follow a typical pattern for multiple generic entries.
Q:What is the split between hepatologists and gastroenterologists prescribing Xifaxan, and how might this change with RED-C?
A:The specific split between hepatologists and gastroenterologists is not available, but the franchise is considered gastroenterology-focused. The RED-C program targets a broader patient population, which could influence prescribing patterns.
Q:What is the likelihood of seeing all-cause mortality data in the initial RED-C top-line results?
A:The initial RED-C top-line results will include primary and important secondary endpoints. The inclusion of all-cause mortality data will depend on the maturity of the data at the time of the readout.
Q:Why did Bausch Health exit the 340B and Medicaid drug rebate programs?
A:Bausch Health exited the 340B and Medicaid drug rebate programs to optimize sales channels and enhance patient assistance programs. The enhanced program offers eligible Medicaid patients access to medicines at no cost with additional benefits like 90-day treatments.
Q:What are the plans for debt refinancing and deleveraging?
A:Deleveraging will primarily rely on free cash flow from operations, supplemented by potential equity raises, capturing debt discounts, or proceeds from asset sales. The B+L equity stake is the most likely candidate for asset sales.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the split between hepatologists and gastroenterologists prescribing Xifaxan, the exact benefits to the company from exiting 340B and Medicaid programs beyond the one-time accrual benefit, and the likelihood of all-cause mortality data in the initial RED-C results.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APAC region
Asia note
BHC progress
Cabtreo Bausch
Cabtreo digit
Canada Lat
Canada investment
Cardizem dermatology
China hand
Conference Instructions
Consolidated Bausch
DURECT cash
DURECT month
EMEA segment
Health Conference
Health platform
IP RD
IP midpoint
JJ result
Lat hand
Lomb team
Revenues decrease
Revenues increase
acquisition DURECT
basis period
charge
decrease basis
environment
flow midpoint
midpoint increase
neurology
nonrecurrence
order
page presentation
priority JJ
volume pricing
BHC Transcript
Bausch Health Companies Inc. (BHC) Presents at Barclays 30th Annual Leveraged Finance Conference 2026 Transcript
Neutral5-19
Bausch Health Companies Inc. (BHC) Q1 2026 Earnings Call Transcript
Positive4-29
The earnings call showed strong financial performance with significant revenue growth in key segments like Salix and Solta, a net debt reduction, and a positive outlook for future growth. Despite some uncertainties, such as potential destocking and tariff impacts, management provided reassuring responses. The acquisition of Shibo and the strategic focus on high-growth areas like China and GI franchise investments are positive indicators. Given the market cap, the stock is likely to react positively, albeit moderately, to these developments.
Bausch Health Companies Inc. (BHC) Q4 2025 Earnings Call Transcript
Positive2-18
The earnings call highlights strong financial performance with increased revenue and reduced debt, alongside optimistic guidance. The company's strategic initiatives, including acquisitions and product launches, are promising. Despite some management vagueness in the Q&A, the overall sentiment is positive, particularly with raised guidance and solid growth in key segments like Xifaxan and Solta. Given the company's market cap, these factors suggest a positive stock price movement in the short term.
Bausch Health Companies Inc. (BHC) Presents at Evercore 8th Annual Healthcare Conference Transcript
Neutral12-2
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
